Technical Analysis for VKTX - Viking Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Flat | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Sell Signal | Bearish | 0.00% | |
| 50 DMA Support | Bullish | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| NR7 | Range Contraction | -8.18% | |
| NR7-2 | Range Contraction | -8.18% | |
| Multiple of Ten Bullish | Other | -8.18% | |
| Wide Bands | Range Expansion | -8.18% | |
| Overbought Stochastic | Strength | -8.18% |
| Alert | Time |
|---|---|
| 50 DMA Support | 1 day ago |
| Down 1 ATR | 1 day ago |
| Down 5% | 1 day ago |
| 60 Minute Opening Range Breakdown | 1 day ago |
| Down 3% | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/21/2024
Viking Therapeutics, Inc. Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders. Its lead clinical program includes VK0612, an orally available drug candidate for the treatment of type 2 diabetes. The company is also developing VK5211, an orally available drug candidate, which has completed Phase I trial for the treatment of cancer cachexia, a disease characterized by an uncontrolled decline in muscle mass. In addition, it is developing VK0214, a novel liver-selective thyroid hormone receptor beta agonist for lipid disorders, such as dyslipidemia and nonalcoholic steatohepatitis, as well as other preclinical programs for metabolic diseases and anemia. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Disease Diabetes Alcohol Medication Treatment Of Cancer Obesity Lipid Hepatitis Steatohepatitis Metabolic Disease Non Alcoholic Fatty Liver Disease Anemia Thyroid Geriatrics Dyslipidemia Rehabilitation Medicine Cachexia Endocrine Disorders Endocrine Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 99.41 |
| 52 Week Low | 8.28 |
| Average Volume | 4,853,024 |
| 200-Day Moving Average | 31.83 |
| 50-Day Moving Average | 73.48 |
| 20-Day Moving Average | 72.11 |
| 10-Day Moving Average | 77.57 |
| Average True Range | 4.88 |
| RSI (14) | 50.50 |
| ADX | 16.8 |
| +DI | 24.33 |
| -DI | 21.90 |
| Chandelier Exit (Long, 3 ATRs) | 67.22 |
| Chandelier Exit (Short, 3 ATRs) | 76.28 |
| Upper Bollinger Bands | 84.24 |
| Lower Bollinger Band | 59.98 |
| Percent B (%b) | 0.56 |
| BandWidth | 33.65 |
| MACD Line | 2.46 |
| MACD Signal Line | 2.11 |
| MACD Histogram | 0.3502 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 84.11 | ||||
| Resistance 3 (R3) | 85.13 | 82.66 | 82.37 | ||
| Resistance 2 (R2) | 82.66 | 79.99 | 82.15 | 81.78 | |
| Resistance 1 (R1) | 78.15 | 78.35 | 76.92 | 77.13 | 81.20 |
| Pivot Point | 75.68 | 75.68 | 75.06 | 75.17 | 75.68 |
| Support 1 (S1) | 71.17 | 73.01 | 69.94 | 70.15 | 66.08 |
| Support 2 (S2) | 68.70 | 71.37 | 68.19 | 65.50 | |
| Support 3 (S3) | 64.19 | 68.70 | 64.92 | ||
| Support 4 (S4) | 63.17 |
